USPTO serial 86266109
SAFETYMAP
Reviewed by CopyMark Law Group
Reg. 4820587Status 710
- Filing date
- Status date
- Registration date
- Sep 29, 2015
- Examiner
- IM, JEAN H
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with SAFETYMAP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrew Baum
Andrew Baum Foley & Lardner LLP3000 K Street, N.W., Suite 600Washington HarbourWashington, DC 20007-5109Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Medical and clinical laboratory apparatus and instruments for next generation sequencing of genomic DNA for the purpose of cancer diagnostic molecular testing, in particular, cancer genomic testing and testing of genomic changes, and related automated decision support tools for diagnostic and therapeutic application, namely, computer application software and hardware for use with the laboratory apparatus and instruments | SECTION 8 - CANCELLED | — |
| 042 | Data collection for scientific research, analytical and clinical purposes, in particular the collection and systematic sorting of patient's specific molecular, genomic and/or clinical data, in particular relating to genomic changes, in particular relating to cancer genomic changes; providing medical research information through the collection and analysis of genetic information and information regarding the treatment of cancer and other diseases and disorders; scientific clinical studies in the field of medicine; data collection for scientific research and analytical purposes, in particular the collection of mathematical and statistical data, clinical data, patient's genomic data and data of clinical studies relating to patient's clinical responses to drug treatments and treatment regimes; compiling data for research and analytical purposes in the field of medical science and diagnostics, in particular compiling patient specific molecular and genomic data, in particular cancer genomic data; scientific, technical and research services, namely, scientific, technical and medical research for medical purposes in the field of medical diagnostic and optimization of treatment regimes; providing medical and scientific research information and scientific research consulting in the fields of pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis and interpretation of analysis services in the field of next generation sequencing (NGS), namely, the analysis and interpretation of data obtained from cancer patients, specifically patient's genomic changes that contribute to a patient's unique cancer disease; providing an online database featuring medical, pharmaceutical, biological and genomic scientific research information for medical and diagnostic purposes; providing an online searchable database in the fields of medical, pharmaceutical, biological, clinical and genomic scientific research information for scientific research, analytical and clinical purposes; providing an online searchable database featuring scientific research in the fields of cancer medicine, translational medicine, interventional epidemiology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis; design and development of computer software in the fields of biology, medicine, and bioinformatics; design and development of computer software for integration of patient's specific data, molecular test results, clinical studies and scientific results; providing online non-downloadable computer software for use by healthcare professionals for medical diagnostic and treatment, in particular in the field of cancer diagnosis and therapy; design and development of databases featuring biomarker data; providing an online searchable database featuring scientific research information in the fields of analysis and optimization of protocols used in cancer treatment, for medical, diagnostic and clinical use; Software as a Service (SAAS) services featuring software for providing information for patient's treatment by enabling the retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical purposes; providing online non-downloadable software for retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical diagnostic and treatment research purposes; medical research and scientific research and scientific consulting services, in particular designing and conducting scientific research drug safety and dosage assessment and drug compatibility studies in the field of cancer therapy for others; providing pharmaceutical scientific and medical research information, in particular research information about drug safety and drug compatibility in relation to cancer therapy and the treatment of individual patients; consulting services in the fields of pharmaceuticals and genetics, in particular conducting scientific research in drug safety and dosage assessment and drug compatibility studies in the field of cancer treatment therapy for others; electronic storage of medical data and information for physicians and healthcare professionals; providing an on-line, non-downloadable computer platform for purposes of storing and providing information about patient's individual cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice | SECTION 8 - CANCELLED | — |
| 044 | Providing online databases featuring medical information and diagnostic, prophylactic and therapeutic properties of pharmaceuticals, and genomic information as it relates to medical diagnosis and treatment; pharmaceutical consulting services in pharmaceuticals and genetics in relation to patient medical treatment options, in particular in the field of clinical diagnostics and therapy, in particular in the field of cancer diagnostics and cancer therapy; medical consulting services with respect to the treatment and diagnosis of individuals with cancer in the fields of clinical pharmacology and the analysis of dose-effect relationships for treatment purposes; medical consulting services in the fields of patient treatments and treatment protocols for cancer | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Molecular Health GmbH
- Other trademarks owned by Molecular Health GmbH
- Other trademarks owned by Molecular Health GmbH
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SAFETYMAP
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 8, 2022 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 29, 2020 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 29, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 14, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 14, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 24, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 26, 2015 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| May 11, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 7, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 15, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 15, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 8, 2015 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Mar 16, 2015 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 16, 2015 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 16, 2015 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 23, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 23, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 16, 2015 | ALIE | ASSIGNED TO LIE | — |
| Feb 12, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 9, 2015 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 9, 2015 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 13, 2014 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2014 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 13, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 11, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| May 14, 2014 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| May 13, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 2, 2014 | NWAP | NEW APPLICATION ENTERED | — |